No Data
No Data
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
RDK79 : Sorry, what’s a pdufa?
Xyno RDK79 : Prescription Drug User Fee Act, means FDA approval or rejection for a drug to go to market. One of the most important events to monitor if you are into pharma companies stock.
RDK79 Xyno : Thank you!
Tonyco : What site is that?